Target attainment of Cefazolin Continuous Infusion for Antibiotic Prophylaxis in patients undergoing CABG surgery
Phase of Trial: Phase II
Latest Information Update: 20 May 2019
Price : $35 *
At a glance
- Drugs Cefazolin (Primary) ; Dalbavancin (Primary)
- Indications Postoperative infections
- Focus Therapeutic Use
- 18 May 2019 Planned End Date changed from 30 Aug 2038 to 11 May 2022.
- 18 May 2019 Planned number of patients changed from 16 to 8.
- 18 May 2018 New trial record